Clinical Trials
13 trialsNCT03242616 2025-04-17
PemVin vs Vin in Previously Treated Metastatic Breast Cancer
Seoul National University Hospital
Phase 2 Completed
NCT02624700 2020-07-14
2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
Virginia Commonwealth University
Phase 2 Terminated
NCT00006007 2016-12-07
LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02829008 2016-07-12
Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients
ChineseAMS
Phase 2 Unknown
NCT00149214 2012-03-21
Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens
Eli Lilly and Company
Phase 2 Completed
NCT00325234 2011-05-20
Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00106002 2009-06-01
Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00063570 2009-05-29
Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy
Eli Lilly and Company
Phase 2 Completed
NCT00102219 2007-11-30
A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00065533 2007-06-22
Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00072865 2007-01-26
Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00191347 2007-01-26
A Study of Biweekly Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00034489 2006-07-19
A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.
Eli Lilly and Company
Phase 2 Completed